Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.86 |
---|---|
High | 4.86 |
Low | 3.70 |
Bid | 3.68 |
Offer | 3.76 |
Previous close | 3.78 |
Average volume | 408.70 |
---|---|
Shares outstanding | 17.39m |
Free float | 8.67m |
P/E (TTM) | -- |
Market cap | 68.15m USD |
EPS (TTM) | -0.9383 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Announcements
- Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
- Exagen Inc. to Participate in Fourth Quarter Investor Conferences
- Exagen Inc. Reports Third Quarter 2024 Results
- Exagen to Announce Third Quarter 2024 Results on November 12, 2024
- Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
- Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
- Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
- Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
- Exagen to Announce Second Quarter 2024 Results on August 5, 2024
More ▼